About: Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate 1 Taken in part from the Ph.D dissertation of A. Das, USC, School of Pharmacy, 1996. 1

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate 1 Taken in part from the Ph.D dissertation of A. Das, USC, School of Pharmacy, 1996. 1 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate 1 Taken in part from the Ph.D dissertation of A. Das, USC, School of Pharmacy, 1996. 1
Creator	Das, Arima Ren, Shijun Lien, Eric Trousdale, Melvin
topic	covid:1567debc904937d07a2dfcfdb67743e2f3c8cd90#this
Source	Elsevier; Medline; PMC
abstract	Abstract Eleven heterocyclic Schiff bases of aminohydroxyguanidine tosylate (SB-AHGs), compounds I–XI, were tested for antiviral activity against herpes simplex virus type 1 (HSV-1) and adenovirus type 5 (Ad 5) via plaque reduction and virus yield reduction assays. This work was undertaken to test the hypothesis that low molecular weight SB-AHGs (MW<235 for the free SB) make better antiviral agents than high MW SB-AHGs (MW>300). The plaque reduction assay method demonstrated that three compounds, I, VII and IX, had moderate activity against HSV-1, with 50% inhibitory concentration (IC50) values of 38.0, 23.5 and 52.1 μM, respectively. Against Ad 5, compounds I, VIII and XI exhibited moderate activity, with IC50 values of 52.7, 19.3 and 5.1 μM, respectively. Among the compounds screened, compound I (1-[(3′-hydroxy-6′-methyl-2′-pyridyl)methylene]amino-3-hydroxyguanidine tosylate) was the most promising antiviral candidate, with selectivity indices (SI) of 10.2 (HSV-1) and 7.6 (Ad 5), respectively. Virus yield reduction assays indicated that compound I had less antiviral potency against HSV-1 than against Ad 5. The antiviral effects of compound I at a high input virus multiplicity of infection (MOI>5) indicated that compound I had effective anti-adenoviral activity at 24 h post infection. This work demonstrated that some of SB-AHGs only have moderate antiviral activities against Ad 5 and HSV-1 viruses. In general, low MW SB-AHGs have low cytotoxicities to the host cells.
has issue date	1999-12-31(xsd:dateTime)
bibo:doi	10.1016/s0166-3542(99)00070-4
bibo:pmid	10651071
has license	els-covid
sha1sum (hex)	1567debc904937d07a2dfcfdb67743e2f3c8cd90
schema:url	https://doi.org/10.1016/s0166-3542%2899%2900070-4
resource representing a document's title	Inhibition of herpes simplex virus type 1 and adenovirus type 5 by heterocyclic Schiff bases of aminohydroxyguanidine tosylate 1 Taken in part from the Ph.D dissertation of A. Das, USC, School of Pharmacy, 1996. 1
has PubMed Central identifier	PMC7125830
has PubMed identifier	10651071
schema:publication	Antiviral Research
resource representing a document's body	covid:1567debc904937d07a2dfcfdb67743e2f3c8cd90#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/1567debc904937d07a2dfcfdb67743e2f3c8cd90
is schema:about of	named entity 'infection' named entity 'values' named entity 'MOI' named entity 'compound' named entity 'Schiff bases' named entity 'tosylate' named entity 'GENERAL' named entity 'EFFECTIVE' named entity 'METHYL' named entity 'HYPOTHESIS' named entity 'MULTIPLICITY' named entity 'MAKE' named entity '50%' named entity 'ACTIVITIES' named entity 'BETTER' named entity 'LOW' named entity 'SELECTIVITY' named entity 'MODERATE' named entity 'YIELD' named entity 'POST' named entity 'HYDROXYGUANIDINE' named entity 'INDICATED' named entity 'HERPES SIMPLEX VIRUS TYPE 1' named entity 'HERPES SIMPLEX VIRUS TYPE 1' named entity 'TOSYLATE' named entity 'SCHIFF BASES' named entity 'POTENCY' named entity 'SCHIFF BASES' named entity 'ANTIVIRAL ACTIVITY' covid:arg/1567debc904937d07a2dfcfdb67743e2f3c8cd90 named entity 'ADENOVIRUS TYPE 5' named entity 'VIRUSES' named entity '283' named entity 'CONCENTRATION' named entity 'INHIBITORY' named entity '1 MM' named entity 'ASSAY METHOD' named entity 'VII' named entity 'PLAQUE' named entity 'DEMONSTRATED' named entity 'ANTIVIRAL AGENTS' named entity 'VIRUS' named entity 'INFECTION' named entity 'COMPOUND' named entity 'LOW MOLECULAR WEIGHT' named entity 'TOSYLATE' named entity 'HAVE' named entity 'REDUCTION' named entity 'ADENOVIRUS TYPE 5' named entity 'HSV-1' named entity 'TO TEST' named entity 'INPUT' named entity 'VIII' named entity 'EFFECTS' named entity 'HOST CELLS' named entity 'WORK' named entity 'CANDIDATE' named entity 'HYDROXY' named entity 'AD 5' named entity 'VALUES' named entity 'INHIBITION' named entity 'MODERATE ACTIVITY' named entity 'ADENOVIRAL' named entity '300' named entity 'ANTIVIRAL' named entity 'INDICES' named entity 'ACTIVITY' named entity 'FREE' named entity 'HIGH' named entity 'TESTED FOR' named entity 'reduction' named entity 'general' named entity 'antiviral' named entity 'activities' named entity 'concentration' named entity 'compound'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software